Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models

Fig. 1

3D185 is a dual FGFR1/2/3 and CSF-1R inhibitor with high selectivity. a Chemical structure of 3D185. B-G, The kinase inhibition curves of 3D185 against FGFR1 (b), FGFR2 (c), FGFR3 (d), FGFR4 (e), KDR (f) and CSF-1R (g). H, A broad kinase profile of 3D185 against 372 protein kinases. I, The effect of 3D185 and AZD4547 on the cell viability of bFGF-induced or VEGF-induced HUVECs. Prestarved primary HUVECs were treated with bFGF or VEGF (100 ng/mL) and 3D185 or AZD4547 for 48 h, and cell viability was then measured using a CCK-8 assay. Representative data from three independent experiments are shown

Back to article page